Dr. Matthew Katz reviews the study that compared neoadjuvant treatment with FOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic cancer.
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.